
|Videos|December 20, 2022
Dr. Dorff on state of second-line treatment for metastatic urothelial cancer
Author(s)Urology Times staff
“First and foremost, it’s great that we have multiple lines of therapy for our bladder cancer patients,” says Tanya Dorff, MD.
Advertisement
Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Annual ACS NCDB report details national trends in prostate cancer care
4
Advice for the Next Generation of Urologists in mCSPC Management
5






